Event / Economy

Trump Pharmaceutical Tariff Order

← All events

Updated

President Trump signed an executive order establishing pharmaceutical tariffs up to 100% for companies without pricing agreements. Companies with favorable pricing deals and U.S. manufacturing investments receive 0% tariffs, while others face graduated rates. The order also modified metal tariffs and affected foreign pharmaceuticals from the EU, Japan, Korea, Switzerland, and the UK.

1 reported locations
Geography of the reported facts
  1. Washington, District of Columbia, United States

The story so far

Daily activity

0 articles
0 articles

2026-08-19 to 2026-11-16 · UTC publication dates

Coverage begins 3 Apr, 02:37 UTC

Follow the documented timeline or explore the related reporting.

What happened

The facts
  1. Trump imposes 25% tariff on products with substantial metal content

    Under the updated metal tariff rules, products containing more than 15% metal by weight will face a 25% tariff on the entire product value. Products with metal content below 15% will only be subject to country-specific tariffs.

    1 corroborating report

  2. Companies with 'most favored nation' pricing deals receive 0% pharmaceutical tariff rate

    Pharmaceutical companies that sign a 'most favored nation' pricing agreement and actively build production facilities in the United States will be exempt from tariffs under the new executive order. The administration has already secured 17 pricing deals with major drugmakers, with 13 agreements signed.

    1 corroborating report

  3. EU, Japan, Korea, and Switzerland receive 15% tariff rate on patented pharmaceuticals

    Under trade frameworks reached with the U.S., the EU, Japan, Korea, and Switzerland will face a 15% tariff on patented pharmaceuticals. The United Kingdom will receive a 10% tariff rate, with the order noting this would reduce to zero under future trade agreements.

    1 corroborating report

  4. Supreme Court previously struck down Trump's broad tariff authority under International Emergency Economic Powers Act

    A February 20 Supreme Court ruling invalidated tariffs Trump imposed using the 1977 International Emergency Economic Powers Act, which had allowed him to immediately impose tariffs on any country at nearly any level. This decision limited Trump's tariff authority but did not prevent sectoral tariffs imposed under other legal provisions.

    1 corroborating report

  5. Trump signs executive order enabling up to 100% tariffs on patented drugs

    President Donald Trump signed an executive order that could impose pharmaceutical tariffs of up to 100% on patented drugs from companies that fail to reach pricing agreements with his administration within specified timeframes. Larger companies have 120 days to negotiate, while others have 180 days before the 100% tariffs would take effect.

    1 corroborating report

  6. Trump updates metal tariffs calculation based on full customs value

    Trump's administration announced changes to how tariffs on imported steel, aluminum, and copper will be calculated, effective Monday. The new approach bases tariff rates on the full customs value of what U.S. customers pay when buying foreign metal. Products fully made of these metals will continue to face 50% tariffs for most countries.

    1 corroborating report

  7. Trump maintains 10% tariff on all imports under separate legal authority

    Trump imposed a 10% tariff on all imports using a separate legal power shortly after the Supreme Court's February ruling. This tariff can only remain in effect for 150 days, and more than two dozen states have challenged it.

    1 corroborating report

  8. PhRMA warns pharmaceutical tariffs could increase medicine costs and jeopardize U.S. investment

    Stephen J. Ubl, CEO of the pharmaceutical trade group PhRMA, cautioned that tariffs on cutting-edge medicines will increase costs and could jeopardize billions in U.S. investments in biopharmaceutical manufacturing. He noted that most medicines sourced from other countries come from reliable U.S. allies.

    1 corroborating report

Read the coverage